A validated HPLC–MS/MS method for the quantification of supinoxin in rat plasma and its application to pharmacokinetic study

• Autorzy: Jeong J.-W. , Seol Y.-H. , Hyun H.-Ch. , Kim H.-R. , Lee J.-H. , Gong Y.-D. , Kang N.-S. , Koo T.-S.

Identyfikatory

DOI

10.1556/1326.2016.00056

• Języki publikacji: EN

Abstrakty

EN

A liquid chromatography–tandem mass spectrometry (LC–MS/MS) method was developed for the quantification of an anticancer drug, supinoxin (RX-5902), in rat plasma. Following precipitation pretreatment using 0.1% formic acid in acetonitrile, separation was performed using a reverse phase liquid chromatography column packed with C18 (3.5 μm, 2.1 × 50 mm) along with a mobile phase of 0.1% formic acid in distilled water and 0.1% formic acid in acetonitrile at a flow rate of 0.3 mL min^-1. Detection was achieved using MS/MS by multiple reaction monitoring via an electrospray ionization source at mass/charge transitions of m/z 442.30 → 223.30 for supinoxin and m/z 430.08 → 223.20 for the internal standard DGG-200064. This method demonstrated a linear standard curve (r = 0.9980) over a supinoxin concentration range of 0.0005–1 μg Ml^-1, as well as intra- and inter-assay precisions below 7.08% and 13.74%, respectively, and an accuracy of 1.15–4.50%. The matrix effect, recovery, and process efficiency were 93.63%, 99.70%, and 93.33%, respectively. Thus, a sensitive and reliable LC–MS/MS method was developed and validated for the quantification of supinoxin in rat plasma. This method was successfully applied to the evaluation of pharmacokinetic studies after single intravenous and oral administration of 1 mg kg^-1 supinoxin in rats.

Słowa kluczowe

EN

Supinoxin; RX-5902; LC–MS/MS; P-p68; pharmacokinetics

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2017
• Tom: Vol. 29, no. 4
• Strony: 463--468
• Opis fizyczny: Bibliogr. 19 poz., rys., tab.

Twórcy

autor

Jeong J.-W.

• Graduate School of New Drug Discovery and Development, Chungnam National University, Republic of Korea

autor

Seol Y.-H.

• Graduate School of New Drug Discovery and Development, Chungnam National University, Republic of Korea

autor

Hyun H.-Ch.

• Graduate School of New Drug Discovery and Development, Chungnam National University, Republic of Korea

autor

Kim H.-R.

• Graduate School of New Drug Discovery and Development, Chungnam National University, Republic of Korea

autor

Lee J.-H.

• Applied Toxicology Research Center, Korea Institute of Toxicology, Republic of Korea

autor

Gong Y.-D.

• Innovative Drug Library Research Center, Department of Chemistry, College of Science, Dongguk University Republic of Korea

autor

Kang N.-S.

• Graduate School of New Drug Discovery and Development, Chungnam National University, Republic of Korea

autor

Koo T.-S.

• Graduate School of New Drug Discovery and Development, Chungnam National University, Republic of Korea

Bibliografia

• [1] Lee Y. B.; Chun G.; Kim D. J.; Ahn C. H.; Kong Y. D.; Jeon M. K.; Kong J. Y. Cancer Res. 2011, 71, 1371.
• [2] Gluck W.; Eckhardt S.; Gutierrez M.; Peterson C.; Benaim E. Eur. J. Cancer 2015, 51, S68 – S69.
• [3] Eckhardt S. G.; Gluck W. L.; Gutierrez M.; Peterson C.; Benaim E. ASCO Annu. Meet. Proc. 2015, 33, TPS2608.
• [4] Causevic M.; Hislop R. G.; Kernohan N. M.; Carey F. A.; Kay R. A.; Steele R. J.; Fuller-Pace F. V. Oncogene 2001, 20, 7734.
• [5] Heinlein U. A. J. Pathol. 1998, 184 , 345.
• [6] Stevenson R. J.; Hamilton S. J.; MacCallum D. E.; Hall P. A.; Fuller-Pace F. V. J. Pathol. 1998, 184, 351.
• [7] Yang L.; Lin C.; Liu Z. R. Mol. Cancer Res. 2005, 3, 355.
• [8] Yang L.; Lin C.; Liu Z. R. Cell 2006, 127, 139.
• [9] Yang L.; Lin C.; Zhao S.; Wang H.; Liu Z. R. J. Biol. Chem. 2007, 282, 16811.
• [10] Wang H.; Gao X.; Yang J. J.; Liu Z. R. Nat. Commu. 2013, 4, 1354.
• [11] Dubey P.; Hendrickson R. C.; Meredith S. C.; Siegel C. T.; Shabanowitz J.; Skipper J. C. ; Engelhard V. H.; Hunt D. F.; Schreiber H. J. Exp. Med. 1997, 185, 695.
• [12] Dai T. Y.; Cao L.; Yang Z. C.; Li Y. S.; Tan L.; Ran X. Z.; Shi C. M. J. Exp. Clin. Cancer Res. 2014, 33, 64.
• [13] Kost G. C.; Yang M. Y.; Li L.; Zhang Y.; Liu C.-Y.; Kim D. J.; Ahn C.-H.; Lee Y. B.; Liu Z.-R. J. Cell. Biochem. 2015, 116, 1595.
• [14] Lee Y. B.; Gong Y. D.; Yoon H.; Ahn C. H.; Jeon M. K.; Kong J. Y. Bioorg. Med. Chem. 2010, 18, 7966.
• [15] Lee Y. B.; Gong Y. D.; Kim D. J.; Ahn C. H.; Kong J. Y.; Kang N. S. Bioorg. Med. Chem. 2012, 20, 1303.
• [16] FDA U. S. Guidance for Industry: Bioanalytical Methods Validation 2001.
• [17] Matuszewski B. K.; Constanzer M. L.; Chavez-Eng C. M. Anal. Chem. 2003, 75, 3019.
• [18] Kim S. J.; Koo T. S.; Ha D. J.; Baek M.; Lee S. K.; Shin D. S.; Moon H. Biomed. Chromatogr. 2012, 26, 371.
• [19] Song J. H.; Kim T. H.; Jung J. W.; Kim N.; Ahn S. H.; Hwang S. O.; Kang N. S.; Yoo S. E.; Koo T. S. Biomed. Chromatogr. 2014, 28, 1112.

Uwagi

Opracowanie rekordu w ramach umowy 509/P-DUN/2018 ze środków MNiSW przeznaczonych na działalność upowszechniającą naukę (2018).